A recent Rheumatology digest,
as sent to subscribers

Study Type: Phase 4, multicentre, single-arm, open-label study

Key Question: Does apremilast reduce peripheral and axial inflammation in psoriatic arthritis patients as measured by whole-body MRI?

Key Findings:

• At 24 and 48 weeks, apremilast significantly reduced total inflammation (least squares mean -3.6 and -3.9 respectively), peripheral joint inflammation (-3.4 and -3.6), and spinal inflammatory lesions (-2.6 and -2.1)
• Reductions in MRI inflammation were more pronounced in patients with moderate versus high baseline disease activity
• 122 patients completed treatment with apremilast 30mg twice daily ± stable methotrexate over 48 weeks

Clinical Relevance: This provides objective MRI evidence supporting apremilast's anti-inflammatory effects across both peripheral and axial PsA manifestations, relevant for UK clinicians considering this oral DMARD option under NICE guidance.

Limitations: Single-arm design without placebo control limits ability to distinguish treatment effects from natural disease variation or regression to the mean.

Study Type: Prospective longitudinal cohort study

Key Question: Do ACPA-positive and ACPA-negative rheumatoid arthritis follow different trajectories from symptom onset through the pre-RA phase to established disease?

Key Findings:

• ACPA-positive patients had longer symptom-to-presentation intervals but shorter presentation-to-RA development times (p=0.006 and p=0.014 respectively)
• ACPA-negative patients experienced more severe morning stiffness throughout and more hand pain/tenderness at all timepoints (p<0.001 for tender joints)
• ACPA-positive patients showed faster CRP elevation and greater subclinical forefoot inflammation in the year before RA diagnosis (p=0.006 and p=0.043 respectively)

Clinical Relevance: These findings suggest ACPA status may guide different prevention strategies in at-risk patients, potentially informing early intervention approaches in NHS rheumatology services.

Limitations: Study limited to patients who ultimately developed RA, excluding those whose symptoms resolved, which may introduce selection bias.

Study Type: Single-cell multiomics study with validation experiments

Key Question: What are the molecular signatures of CD4+ T cells in proteinase 3-ANCA-positive granulomatosis with polyangiitis (PR3-GPA) that associate with disease activity?

Key Findings:

• CD4+ T cells from patients with active PR3-GPA showed upregulated PIM1, SOCS3, and STAT3 expression compared to controls, with increased STAT3 phosphorylation and serum IL-6 levels
• Pim kinase inhibition reduced CD4+ T-cell activation, proliferation, and cytokine production in functional assays
• Spatial transcriptomics of kidney biopsies confirmed upregulated STAT3 and PIM kinase expression in inflamed glomerulonephritis tissue

Clinical Relevance: This study identifies the STAT3-PIM1 pathway as a potential therapeutic target in PR3-GPA, suggesting JAK-STAT inhibitors (already available in NHS formularies) and Pim kinase inhibitors warrant investigation as treatment options.

Limitations: The study focused on peripheral blood T cells with limited tissue validation, and functional inhibition studies were performed ex vivo rather than in clinical trials.

Study Type: Comparative transcriptomic and functional analysis

Key Question: Do synovial fibroblasts from RA-risk individuals show early metabolic changes that precede clinical arthritis development?

Key Findings:

• RA-risk and RA synovial fibroblasts showed reduced lipid droplet content compared to controls due to enhanced lipolysis driven by decreased G0S2 expression
• This metabolic dysfunction occurred even before clinical arthritis development in at-risk individuals
• Inhibiting lipolysis or stimulating G0S2 expression reduced the myeloid-supporting inflammatory phenotype of synovial fibroblasts

Clinical Relevance: Identifies early metabolic biomarkers in pre-clinical RA that could inform risk stratification and early intervention strategies for seropositive at-risk patients in UK rheumatology services.

Limitations: Study design prevents determination of whether metabolic changes are causative or consequential in RA development.

Study Type: Retrospective analysis using global burden of disease data

Key Question: What are the epidemiological trends and economic costs of musculoskeletal disorders in high-income countries from 1990-2023?

Key Findings:

• Total incident cases, prevalent cases, and disability-adjusted life years increased by 37%, 54%, and 49% respectively between 1990-2023, despite 4% decrease in age-standardised incidence
• Direct medical costs reached $327.68 billion in 2023, with USA contributing >45%
• Obesity-related burden increased from 8.3% to 10.7% of disability years, while smoking-related burden decreased by 30%

Clinical Relevance: This demonstrates the growing absolute burden of musculoskeletal disease in developed healthcare systems like the NHS, highlighting the need for targeted obesity and occupational health interventions despite overall healthcare improvements.

Limitations: Analysis relies on Global Burden of Disease database estimates which may have methodological variations across countries and time periods.

Study Type: Genome-wide association study (MHC-focused meta-analysis)

Key Question: What genetic variants within the major histocompatibility complex region are associated with interstitial lung disease development in systemic sclerosis?

Key Findings:

• Analysis of 5,962 SSc patients (2,412 with ILD) identified 12 significant HLA associations across class I and II genes
• Class I HLA variants remained significant after adjusting for anti-topoisomerase antibodies, while class II variant significance was reduced
• Composite prediction model incorporating genetic, clinical, and demographic variables achieved AUC 0.754 for SSc-ILD risk

Clinical Relevance: This research could inform development of genetic risk stratification tools to identify SSc patients at highest risk of developing ILD, potentially enabling earlier monitoring and intervention in UK rheumatology practice.

Limitations: Study limited to European ancestry populations, which may limit generalisability to the diverse UK population.

Study Type: Cross-sectional multiomics study with discovery and validation cohorts

Key Question: Can conserved molecular subtypes be identified across rheumatoid arthritis, systemic lupus erythematosus, and primary Sjögren's syndrome using integrated transcriptomic and epigenomic profiling?

Key Findings:

• Two reproducible molecular subtypes identified across all three diseases: megakaryocyte-enriched and B-cell-enriched subtypes, validated in 262 treatment-naïve patients
• Megakaryocyte-enriched subtype associated with higher platelet counts, increased disease activity, and broader organ involvement
• Distinct epigenetic regulatory programmes identified for each subtype, with specific super-enhancer patterns driving lineage-specific gene expression

Clinical Relevance: This cross-disease molecular classification could enable precision stratification of patients with systemic autoimmune diseases and guide development of targeted therapies based on underlying cellular programmes rather than traditional diagnostic categories.

Limitations: Single-centre study in Chinese Han population limits generalisability to UK multi-ethnic patient cohorts.

Study Type: Experimental study (in vitro, murine models, and ex vivo human tissue)

Key Question: Does the nuclear receptor TR4 drive fibroblast activation and tissue fibrosis in systemic sclerosis?

Key Findings:

• TR4 expression was upregulated in SSc patient skin fibroblasts and induced by TGFβ in a SMAD3-dependent manner
• TR4 knockdown prevented fibroblast-to-myofibroblast transition and ameliorated experimental skin and pulmonary fibrosis in multiple murine models
• TR4's profibrotic effects operated through Gα12/ROCK-dependent cytoskeletal remodeling pathways

Clinical Relevance: This identifies TR4 as a potential novel therapeutic target for SSc, addressing the significant unmet need for effective antifibrotic treatments in NHS rheumatology services.

Limitations: Translation from murine models and ex vivo human tissue to clinical efficacy remains to be demonstrated.